ArticleJournal for immunotherapy of cancer2021

Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.